Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NanoViricides President Presents at the 2nd Annual Conference of the American Society for NanoMedicine

Abstract:
NanoViricides, Inc. (the "Company"), announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

NanoViricides President Presents at the 2nd Annual Conference of the American Society for NanoMedicine

West Haven, CN | Posted on October 18th, 2010

This was a joint meeting, co-sponsored by the Office of AIDS Research, National Institutes of Health (NIH), the Division of AIDS, National Institute of Allergy and Infectious Diseases of the NIH, and ASNM. The conference was held at the Bolger Center, Washington, DC, October 14-16, 2010. Anil R Diwan, PhD, President of the Company, spoke in the panel on "Policy, Patents, and Commercialization". The panel covered the business challenges that nanomedicine companies face in bringing leading edge medical products into commercialization.

"Nanomedicines represent the next therapeutic plateau in the treatment of many diseases," said Dr. Diwan, adding, "The level of effectiveness achieved with these novel, targeted, specific, therapies is far greater than what has been attained thus far."

Dr. Diwan reviewed the accomplishments of NanoViricides, Inc. He discussed the platform technology upon which the nanoviricides(R) drug candidates are based. Nanoviricides are designed to complete the job of rendering the virus particle non-infectious without assistance from the immune system, he said. A nanoviricide accomplishes this by mimicking the features of the cell surface to which a virus binds. He presented the very promising results obtained by the Company in testing its nanoviricides drug candidates against a number of diseases including Influenza, viral diseases of the Eye, Herpes Simplex Virus (HSV), Dengue Virus, and HIV. He then went on to discuss the challenges faced by nanomedicine companies in commercializing novel, cutting edge therapies. The presentation was attended by leading scientists in the field of nanomedicine as well as scientists from the sponsoring NIH agencies. The presentation was well received.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

####

About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

About the American Society for NanoMedicine (ASNM)
The American Society for NanoMedicine (ASNM) is a professional, academic and medical society dedicated to advancing research in nanomedicine. It comprises of members drawn from throughout the fields of nanotechnology, engineering, and the biomedical sciences with the common goal of advancing nanomedicine research for the realization of the potential it has to benefit the global community. ASNM is an open, democratic, and professional nonprofit organization.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200

Copyright © NanoViricides

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. Announces Next Large Order from the Oil and Gas Industry March 26th, 2015

Quantum compute this -- WSU mathematicians build code to take on toughest of cyber attacks: Revamped knapsack code offers online security for the future March 26th, 2015

Thousands of atoms entangled with a single photon: Result could make atomic clocks more accurate March 26th, 2015

Square ice filling for a graphene sandwich March 26th, 2015

Nanomedicine

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Announcements

Industrial Nanotech, Inc. Announces Next Large Order from the Oil and Gas Industry March 26th, 2015

Quantum compute this -- WSU mathematicians build code to take on toughest of cyber attacks: Revamped knapsack code offers online security for the future March 26th, 2015

Thousands of atoms entangled with a single photon: Result could make atomic clocks more accurate March 26th, 2015

Square ice filling for a graphene sandwich March 26th, 2015

Events/Classes

LAMDAMAP 2015 hosted by the University March 26th, 2015

SUNY POLY CNSE to Host First Ever Northeast Semi Supply Conference (NESCO) Conference Will Connect New and Emerging Innovators in the Northeastern US and Canada with Industry Leaders and Strategic Investors to Discuss Future Growth Opportunities in NYS March 25th, 2015

NNI Publishes Workshop Report Assessing the Status of EHS Risk Science: Report examines progress three years after the release of the 2011 NNI EHS Research Strategy March 23rd, 2015

EEE Photonics Society’s Fourth Annual Optical Interconnects Conference Seeks to Bring Together the Latest Advanced Optical Interconnect Technologies, Systems & Architectures for the Next Generation of Supercomputers & Datacenters March 23rd, 2015

Nanobiotechnology

Dolomite’s microfluidics technology ideal for B cell encapsulation March 24th, 2015

Tiny bio-robot is a germ suited-up with graphene quantum dots March 24th, 2015

TGAC's take on the first portable DNA sequencing 'laboratory': First remote laboratory allows researchers to conduct real-time anaylsis March 19th, 2015

Super-resolution microscopes reveal the link between genome packaging and cell pluripotency: A study using super-resolution microscopy reveals that our genome is not regularly packaged and links these packaging differences to stem cell state March 12th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE